Skip to content


EU Ocuther

This project has received funding from the European Union’s Horizon 2020 research and  innovation  programme under the Marie Skłodowska-Curie grant agreement No 722717.


(Recruitment has ended) 

Fifteen Early Stage Researcher (ESR) vacancies in the Marie Sklodowska-Curie Innovative Training Network

We shall educate 15 Early Stage Researchers in a network where they will receive tailored, multi-disciplinary and inter-sectoral education in preclinical ocular drug development. The thesis projects are directed to the drug treatment of retinal diseases, the major challenge in the field. The proposal combines new drug candidates from the experts of ophthalmology, innovative drug delivery technologies from pharmaceutical scientists and companies, and modern in vitro, in silico and in vivo methods from various partners. The thesis projects include secondments in academic and industrial partner laboratories and course programme that encompasses the relevant fields in ocular drug development. Therefore, this proposal presents unique combination of innovation and education in the field with obvious need for such education. The ESRs and other outcomes of this project will greatly benefit the future competitiveness of European science and industry in this field of expanding importance.

Required background: MSc degree in an appropriate field of science (e.g. pharmacy, medicine, chemistry, biology).

Below you can find details on the applications for the OCUTHER – European Training Network within Marie Sklodowska Curie Programme – what we have to offer, the required background and what we expect from you.

The deadline for applications for ESR 10 at the University of Padova, Italy has been extended to June 16, 2017.

ESR1: Kinetic modelling of drugs and nanocarriers in the posterior eye segment; University of Eastern  Finland (Finland)

ESR2: Profiling of ADME properties of drug candidates and retinal cells models; University of Eastern Finland (Finland)

ESR3: Pathogenesis of age-related macular degeneration (AMD); University of Eastern Finland (Finland)

ESR4: Effects of sustained delivery of VCP inhibitors in animal models of retinitis pigmentosa; Eberhard-Karls-University, Tübingen (Germany)

ESR5: Effects of intravitreal slow controlled release of neurotrophic retinal Müller glial cell (RMC)-derived factors; Tübingen University (Germany)

ESR6: Ocular response to Nanoparticles to be used for intraocular drug delivery; Queen’s University Belfast (UK)

ESR7: Sustained intraocular drug delivery for the management of inflammation induced retinal angiogenesis; Queen’s University Belfast (UK)

ESR8: Non-invasive pharmacological treatment of retinal degeneration in the Bardet-Biedl Syndrome and related ciliopathies (Strasbourg Univ., France)

ESR9: Protein cages modified for cell selective delivery of siRNA to retinal cells; Eindhoven University of  Technology  (TU/e, The Netherlands)

ESR10: Supramolecular bioconjugates for ocular delivery; University of Padova (Italy)

ESR11: Multifunctional colloidal formulations for ocular delivery; University of Padova (Italy)

ESR12: Development of sustained release formulations for ocular delivery; Utrecht University (The Netherlands)

ESR13: Focused ultrasound (FUS) in ocular drug delivery; Utrecht University/University Medical Centre Utrecht Utrecht, The Netherlands)

ESR14: Magnetic Nanoparticles for Retinal Delivery; OZ Biosciences (OZB) (France)

ESR15: Development of a physiologically based systems pharmacology model of the eye; Simcyp (UK)